Literature DB >> 27630278

Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma.

Marius Raica1, Adriana-Andreea Jitariu1, Anca Maria Cimpean2.   

Abstract

Cutaneous malignant melanoma is an aggressive tumor characterized by early lymph node metastasis and bad prognosis. Although the spread of tumor cells in the regional lymph nodes is very important in the staging, prognosis and therapeutic strategy of malignant melanoma, the mechanism(s) of initial lymphatic vessels invasion is are) not completely understood. In the present review, we analyze the main factors involved in melanoma-associated lymphangiogenesis, based on existing available evidence. Currently, there are no anti-lymphangiogenic drugs approved for clinical trials. On the other hand, inhibition of lymph node metastasis has been demonstrated in experimental models by inhibiting tumor-associated lymphangiogenesis. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Lymphangiogenesis; anti-lymphangiogenic therapy; growth factors; lymph node metastasis; malignant melanoma; prognosis; review

Mesh:

Substances:

Year:  2016        PMID: 27630278     DOI: 10.21873/anticanres.10986

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  S100A4-dependent glycolysis promotes lymphatic vessel sprouting in tumor.

Authors:  Anqi Li; Linyu Zhu; Ningjing Lei; Jiajia Wan; Xixi Duan; Shuangqing Liu; Yanru Cheng; Ming Wang; Zhuoyu Gu; Huilei Zhang; Yueyue Bai; Li Zhang; Fazhan Wang; Chen Ni; Zhihai Qin
Journal:  Angiogenesis       Date:  2022-07-12       Impact factor: 10.658

2.  Metastatic Gallbladder Melanoma Presenting as Acute Emphysematous Cholecystitis.

Authors:  Natalie Hall; Nicole L Grenier; Samir A Shah; Richard Gold; Edward Feller
Journal:  Case Rep Med       Date:  2018-05-08

Review 3.  Cellular and Molecular Heterogeneity Associated with Vessel Formation Processes.

Authors:  Pollyana Ribeiro Castro; Alan Sales Barbosa; Jousie Michel Pereira; Hedden Ranfley; Mariane Felipetto; Carlos Alberto Xavier Gonçalves; Isabela Ribeiro Paiva; Bárbara Betônico Berg; Luciola Silva Barcelos
Journal:  Biomed Res Int       Date:  2018-10-10       Impact factor: 3.411

4.  The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.

Authors:  Marcela García; Maria Belen Palma; Jerome Verine; Santiago Miriuka; Ana M Inda; Ana L Errecalde; François Desgrandchamps; Edgardo D Carosella; Diana Tronik-Le Roux
Journal:  BMC Cancer       Date:  2020-07-03       Impact factor: 4.430

5.  Evaluation of Nanotargeted 111In-Cyclic RGDfK-Liposome in a Human Melanoma Xenotransplantation Model.

Authors:  Si-Yen Liu; Sheng-Nan Lo; Wan-Chi Lee; Wei-Chuan Hsu; Te-Wei Lee; Chih-Hsien Chang
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 6.  Dissecting the Lymphatic System to Predict Melanoma Metastasis.

Authors:  Rishi Suresh; Arturas Ziemys; Ashley M Holder
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

Review 7.  Hypoxia-dependent drivers of melanoma progression.

Authors:  Simona D'Aguanno; Fabiana Mallone; Donatella Del Bufalo; Antonietta Moramarco; Marco Marenco
Journal:  J Exp Clin Cancer Res       Date:  2021-05-08

Review 8.  Lymphatic Vessel Regression and Its Therapeutic Applications: Learning From Principles of Blood Vessel Regression.

Authors:  Faisal Masood; Rohan Bhattaram; Mark I Rosenblatt; Andrius Kazlauskas; Jin-Hong Chang; Dimitri T Azar
Journal:  Front Physiol       Date:  2022-03-22       Impact factor: 4.755

9.  Exosomes as a Communication Tool Between the Lymphatic System and Bladder Cancer.

Authors:  Rebekah J Park; Yeo Jin Hong; Yifan Wu; Paul Myungchul Kim; Young-Kwon Hong
Journal:  Int Neurourol J       Date:  2018-09-28       Impact factor: 2.835

Review 10.  Heterogeneity of tumor lymphangiogenesis: Progress and prospects.

Authors:  Xueting Hu; Jincai Luo
Journal:  Cancer Sci       Date:  2018-08-23       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.